| Submit your comments on this article | |
| Science & Technology | |
| Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial | |
| 2026-06-07 | |
| [Reuters] Pfizer presented data on Saturday showing that the mean nausea rate in all the arms of the VESPER-3 study was around 38% and the mean vomiting rate was about 23.3%. Last month, JP Morgan analyst Chris Schott said that investors would be looking for the vomiting rate for the drug in the trial to be "20-25% or lower." Around 25% of patients on Novo Nordisk's Wegovy vomited during that company's weight-loss trial, while around 44% reported nausea. Bizarre
| |
| Posted by:Skidmark |
| #1 |
| Posted by: Skidmark 2026-06-07 09:50 |